5-Amino-1MQ (50 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once or twice daily subcutaneously. Due to the compound's plasma half-life of approximately

Reconstitution Steps

1. Remove the vial from freezer storage and allow to equilibrate at room temperature for 15 to 20 minutes.
2. Draw 4.0 mL bacteriostatic water with a sterile syringe.
3. Inject slowly down the vial wall; avoid foaming.
4. Gently swirl until dissolved (solution should be clear; do not shake).
5. Label and refrigerate at 2 to 8 °C, protected from light; use within 2 to 4 weeks. At 12.5 mg/mL, 1 unit = 0.01 mL = 0.125 mg (125 mcg) on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C in dry, dark conditions; stable up to 24 months.
• Reconstituted: refrigerate at 2 to 8 °C; use within 2 to 4 weeks.
• Allow vials to reach room temperature before reconstitution to prevent condensation and pressure

issues.

• Do not refreeze reconstituted solution.

Supplies Needed

Plan based on research duration using the 50 mg vial format at 5 mg/day.

5-Amino-1MQ Vials (50 mg each):

• 1 week (5 mg/day): ~1 vial. 2 weeks: ~1 vial. 4 weeks: ~2 vials.

Insulin Syringes (U-100):

• Per week (once daily): 7 syringes.
• Per week (BID): 14 syringes.
• 4 weeks (once daily): 28 syringes.

Bacteriostatic Water (10 mL bottles):

• 1 week (1 vial): 1 bottle. 4 weeks (2 vials): 1 bottle.

Alcohol Swabs:

• Per week (once daily): 14 swabs.
• 4 weeks: 56 swabs (1 x 100-count box).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each administration; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; a mild stinging sensation may occur due to the quinolinium structure.
• Document daily dose and site rotation to maintain consistency.
• The 50 mg vial format is ideal for extended research cycles; a single vial can last 10 to 20 days.

How This Works

5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule that selectively inhibits Nicotinamide N-methyltransferase (NNMT). NNMT is an enzyme that methylates nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor. In states of obesity and metabolic dysfunction, NNMT is often overexpressed in adipose tissue, depleting nicotinamide and reducing NAD+ availability. By inhibiting NNMT, 5-Amino-1MQ may spare nicotinamide for NAD+ synthesis, thereby activating SIRT1 (Sirtuin 1) pathways associated with mitochondrial biogenesis and fat oxidation. Preclinical studies indicate that NNMT knockdown or inhibition can protect against diet-induced weight gain and improve metabolic parameters without reducing food intake.

Benefits & Side Effects

Observations from preclinical and early research literature.

• May support reductions in fat mass while preserving lean muscle in animal models.
• Associated with elevated NAD+ levels and SIRT1 activation in preclinical studies.
• Enhanced grip strength observed in aged mice when combined with exercise.
• Generally well tolerated; occasional reports of mild headache, transient jitteriness, or injection-site

reactions.

• Long-term human safety data not established; this compound remains investigational.

Lifestyle Factors

Complementary strategies for best outcomes.

• Pair with a balanced, protein-forward diet tailored to energy needs.
• Combine resistance training and aerobic activity; preclinical data suggest synergy with exercise.
• Prioritize sleep and stress management to support metabolic adaptation.
• Consider complementary NAD+ precursors (NMN/NR) per emerging stack protocols.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity (Nature Medicine, 2014).
2. NNMT inhibition mitigates obesity-related metabolic dysfunctions (PMC, 2024).
3. NNMT: a novel therapeutic target for metabolic syndrome (Frontiers in Pharmacology, 2024).
4. LC-MS/MS assay for 5-amino-1-methylquinolinium: pharmacokinetic and oral bioavailability study (PubMed, 2021).